Coronary artery calcification, an improvement in risk classification: Need for reappraisal?

Daniel Duprez

doi:10.1016/j.jacc.2010.06.027

Coronary artery calcification, an improvement in risk classification: Need for reappraisal?

Daniel Duprez

Medicine - Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	1415-1417
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	56
Issue number	17
DOIs	https://doi.org/10.1016/j.jacc.2010.06.027
State	Published - Oct 19 2010

Bibliographical note

Funding Information:
Dr. Duprez has received honoraria as consultant for Novartis and Pfizer; honoraria as member of speaker's bureau for Pfizer, Novartis, Merck, and Forest; and research grants from Roche and Novartis .

Keywords

Framingham risk estimate
coronary calcium score
coronary heart disease
intermediate risk

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jacc.2010.06.027

Find It

Find It at U of M Libraries

Cite this

@article{e28d97da893d439f9cf1606ced75632b,

title = "Coronary artery calcification, an improvement in risk classification: Need for reappraisal?",

keywords = "Framingham risk estimate, coronary calcium score, coronary heart disease, intermediate risk",

author = "Daniel Duprez",

note = "Funding Information: Dr. Duprez has received honoraria as consultant for Novartis and Pfizer; honoraria as member of speaker's bureau for Pfizer, Novartis, Merck, and Forest; and research grants from Roche and Novartis . ",

year = "2010",

month = oct,

day = "19",

doi = "10.1016/j.jacc.2010.06.027",

language = "English (US)",

volume = "56",

pages = "1415--1417",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "17",

}

TY - JOUR

T1 - Coronary artery calcification, an improvement in risk classification

T2 - Need for reappraisal?

AU - Duprez, Daniel

N1 - Funding Information: Dr. Duprez has received honoraria as consultant for Novartis and Pfizer; honoraria as member of speaker's bureau for Pfizer, Novartis, Merck, and Forest; and research grants from Roche and Novartis .

PY - 2010/10/19

Y1 - 2010/10/19

KW - Framingham risk estimate

KW - coronary calcium score

KW - coronary heart disease

KW - intermediate risk

UR - http://www.scopus.com/inward/record.url?scp=77957923371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957923371&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2010.06.027

DO - 10.1016/j.jacc.2010.06.027

M3 - Editorial

C2 - 20946999

AN - SCOPUS:77957923371

SN - 0735-1097

VL - 56

SP - 1415

EP - 1417

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 17

ER -

Coronary artery calcification, an improvement in risk classification: Need for reappraisal?

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Cite this